Pharmacokinetics and Pharmacodynamics of the Glucagon Receptor Antagonist LGD-6972 in a Multi-dose Clinical Trial

被引：0
|
作者：
Vajda, Eric G.
Logan, Douglas
Lasseter, Kenneth
Armas, Danielle
Plotkin, Diane
Pipkin, J. D.
Li, Yong-Xi
Zhou, Rong
Klein, David
Wei, Xiaoxiong
Dilzer, Stacy
Zhi, Lin
Marschke, Keith B.
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1193-P
引用
收藏
页码：A308 / A308
页数：1
相关论文
共 50 条
  • [41] Single-and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
    Sidharta, Patricia N.
    Melchior, Meggane
    Kankam, Martin K.
    Dingemanse, Jasper
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 949 - 964
  • [42] CLINICAL SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-246475: A SELECTIVE REVERSIBLE P2Y12 RECEPTOR ANTAGONIST.
    Juif, P. -E.
    Boehler, M.
    Ufer, M.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S71 - S71
  • [43] An Open-Label Clinical Trial of the Effects of Age and Gender on the Pharmacodynamics, Pharmacokinetics and Safety of the Ghrelin Receptor Agonist Anamorelin
    Leese, Philip T.
    Trang, John M.
    Blum, Robert A.
    de Groot, Eleanor
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (02): : 112 - 120
  • [44] A NEW REVERSIBLE AND POTENT P2Y12 RECEPTOR ANTAGONIST: TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS IN A FIRST-IN-MAN TRIAL.
    Baldoni, D.
    Krause, A.
    Bruderer, S.
    Astruc, B.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S34 - S34
  • [45] A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes
    Fraser, Iain P.
    Neufeld, Naomi D.
    Fox, Larry A.
    Kipnes, Mark S.
    Miller, Tracie L.
    Zeitler, Philip S.
    Rodriguez, Henry
    Gilmartin, Jocelyn H.
    Lee, Susan J.
    Patterson, Jaclyn K.
    Li, Xiujiang S.
    Maganti, Lata
    Luo, Wen-Lin
    Tatosian, Daniel A.
    Stoch, S. Aubrey
    PEDIATRIC DIABETES, 2019, 20 (01) : 48 - 56
  • [46] Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial
    Boeder, Schafer C.
    Thomas, Robert L.
    Le Roux, Melissa J.
    Giovannetti, Erin R.
    Gregory, Justin M.
    Pettus, Jeremy H.
    DIABETES CARE, 2025, 48 (01)
  • [47] Anakinra Pilot - a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
    Green, Elys A.
    Metz, David
    Galinsky, Robert
    Atkinson, Rebecka
    Skuza, Elizbeth M.
    Clark, Megan
    Gunn, Alistair J.
    Kirkpatrick, Carl M.
    Hunt, Rod W.
    Berger, Philip J.
    Nold-Petry, Claudia A.
    Nold, Marcel F.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] MULTIPLE-ASCENDING-DOSE STUDY OF ACT-541468, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST: CHARACTERIZATION OF ITS MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY
    Muehlan, C.
    Brooks, S.
    Zuiker, R.
    van Gerven, J.
    Dingemanse, J.
    SLEEP, 2018, 41 : A3 - A3
  • [49] Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults
    Landry, Ishani
    Nakai, Kenya
    Ferry, Jim
    Aluri, Jagadeesh
    Hall, Nancy
    Lalovic, Bojan
    Moline, Margaret L.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (02): : 153 - 165
  • [50] Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial
    Ge, Junbo
    Zhu, Junren
    Hong, Bum-Kee
    Boonbaichaiyapruck, Sarana
    Goh, Yew Seong
    Hou, Charles Jia-Yin
    Pinton, Philippe
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (09) : 2077 - 2085
12345